Economic considerations and patients’ preferences affect treatment selection for rheumatoid arthritis patients: A discrete choice experiment among European rheumatologists

M Hifinger (Corresponding Author), M Hiligsmann, S Ramiro, V Watson, J L Severens, B Fautrel, T Uhlig, R van Vollenhoven, P Jacques, J Detert, J Canas da Silva, C A Scire, F Berghea, L Carmona, M Pentek, A Keat, A Boonen

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Objective: To compare the value that rheumatologists across Europe attach to patients' preferences and economic aspects when choosing treatments for patients with rheumatoid arthritis.

Methods: In a discrete choice experiment, European rheumatologists chose between two hypothetical drug treatments for a patient with moderate disease activity. Treatments differed in five attributes: efficacy (improvement and achieved state on disease activity), safety (probability of serious adverse events), patient's preference (level of agreement), medication costs and cost-effectiveness (incremental cost-effectiveness ratio (ICER)). A Bayesian efficient design defined 14 choice sets, and a random parameter logit model was used to estimate relative preferences for rheumatologists across countries. Cluster analyses and latent class models were applied to understand preference patterns across countries and among individual rheumatologists.

Results: Responses of 559 rheumatologists from 12 European countries were included in the analysis (49% females, mean age 48 years). In all countries, efficacy dominated treatment decisions followed by economic considerations and patients’ preferences. Across countries, rheumatologists avoided selecting a treatment that patients disliked. Latent class models revealed four respondent profiles: one traded off all attributes except safety, and the remaining three classes disregarded ICER. Among individual rheumatologists, 57% disregarded ICER and these were more likely from Italy, Romania, Portugal or France, whereas 43% disregarded uncommon/rare side effects and were more likely from Belgium, Germany, Hungary, the Netherlands, Norway, Spain, Sweden or UK.

Conclusions: Overall, European rheumatologists are willing to trade between treatment efficacy, patients' treatment preferences and economic considerations. However, the degree of trade-off differs between countries and among individuals.
Original languageEnglish
Pages (from-to)126-132
Number of pages7
JournalAnnals of the Rheumatic Diseases
Volume76
Issue number1
Early online date17 May 2016
DOIs
Publication statusPublished - 1 Jan 2017

Fingerprint

Patient Preference
Cost effectiveness
Rheumatoid Arthritis
Economics
Patient treatment
Cost-Benefit Analysis
Experiments
Drug therapy
Therapeutics
Safety
Romania
Portugal
Rheumatologists
Hungary
Belgium
Norway
Sweden
Netherlands
Spain
Italy

Cite this

Economic considerations and patients’ preferences affect treatment selection for rheumatoid arthritis patients : A discrete choice experiment among European rheumatologists. / Hifinger, M (Corresponding Author); Hiligsmann, M; Ramiro, S; Watson, V; Severens, J L; Fautrel, B; Uhlig, T; van Vollenhoven, R; Jacques, P; Detert, J; Canas da Silva, J; Scire, C A; Berghea, F; Carmona, L; Pentek, M; Keat, A; Boonen, A.

In: Annals of the Rheumatic Diseases, Vol. 76, No. 1, 01.01.2017, p. 126-132.

Research output: Contribution to journalArticle

Hifinger, M, Hiligsmann, M, Ramiro, S, Watson, V, Severens, JL, Fautrel, B, Uhlig, T, van Vollenhoven, R, Jacques, P, Detert, J, Canas da Silva, J, Scire, CA, Berghea, F, Carmona, L, Pentek, M, Keat, A & Boonen, A 2017, 'Economic considerations and patients’ preferences affect treatment selection for rheumatoid arthritis patients: A discrete choice experiment among European rheumatologists', Annals of the Rheumatic Diseases, vol. 76, no. 1, pp. 126-132. https://doi.org/10.1136/annrheumdis-2016-209202
Hifinger, M ; Hiligsmann, M ; Ramiro, S ; Watson, V ; Severens, J L ; Fautrel, B ; Uhlig, T ; van Vollenhoven, R ; Jacques, P ; Detert, J ; Canas da Silva, J ; Scire, C A ; Berghea, F ; Carmona, L ; Pentek, M ; Keat, A ; Boonen, A. / Economic considerations and patients’ preferences affect treatment selection for rheumatoid arthritis patients : A discrete choice experiment among European rheumatologists. In: Annals of the Rheumatic Diseases. 2017 ; Vol. 76, No. 1. pp. 126-132.
@article{eaedb730d0a94868836914865af9f14c,
title = "Economic considerations and patients’ preferences affect treatment selection for rheumatoid arthritis patients: A discrete choice experiment among European rheumatologists",
abstract = "Objective: To compare the value that rheumatologists across Europe attach to patients' preferences and economic aspects when choosing treatments for patients with rheumatoid arthritis.Methods: In a discrete choice experiment, European rheumatologists chose between two hypothetical drug treatments for a patient with moderate disease activity. Treatments differed in five attributes: efficacy (improvement and achieved state on disease activity), safety (probability of serious adverse events), patient's preference (level of agreement), medication costs and cost-effectiveness (incremental cost-effectiveness ratio (ICER)). A Bayesian efficient design defined 14 choice sets, and a random parameter logit model was used to estimate relative preferences for rheumatologists across countries. Cluster analyses and latent class models were applied to understand preference patterns across countries and among individual rheumatologists.Results: Responses of 559 rheumatologists from 12 European countries were included in the analysis (49{\%} females, mean age 48 years). In all countries, efficacy dominated treatment decisions followed by economic considerations and patients’ preferences. Across countries, rheumatologists avoided selecting a treatment that patients disliked. Latent class models revealed four respondent profiles: one traded off all attributes except safety, and the remaining three classes disregarded ICER. Among individual rheumatologists, 57{\%} disregarded ICER and these were more likely from Italy, Romania, Portugal or France, whereas 43{\%} disregarded uncommon/rare side effects and were more likely from Belgium, Germany, Hungary, the Netherlands, Norway, Spain, Sweden or UK.Conclusions: Overall, European rheumatologists are willing to trade between treatment efficacy, patients' treatment preferences and economic considerations. However, the degree of trade-off differs between countries and among individuals.",
author = "M Hifinger and M Hiligsmann and S Ramiro and V Watson and Severens, {J L} and B Fautrel and T Uhlig and {van Vollenhoven}, R and P Jacques and J Detert and {Canas da Silva}, J and Scire, {C A} and F Berghea and L Carmona and M Pentek and A Keat and A Boonen",
year = "2017",
month = "1",
day = "1",
doi = "10.1136/annrheumdis-2016-209202",
language = "English",
volume = "76",
pages = "126--132",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",
number = "1",

}

TY - JOUR

T1 - Economic considerations and patients’ preferences affect treatment selection for rheumatoid arthritis patients

T2 - A discrete choice experiment among European rheumatologists

AU - Hifinger, M

AU - Hiligsmann, M

AU - Ramiro, S

AU - Watson, V

AU - Severens, J L

AU - Fautrel, B

AU - Uhlig, T

AU - van Vollenhoven, R

AU - Jacques, P

AU - Detert, J

AU - Canas da Silva, J

AU - Scire, C A

AU - Berghea, F

AU - Carmona, L

AU - Pentek, M

AU - Keat, A

AU - Boonen, A

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Objective: To compare the value that rheumatologists across Europe attach to patients' preferences and economic aspects when choosing treatments for patients with rheumatoid arthritis.Methods: In a discrete choice experiment, European rheumatologists chose between two hypothetical drug treatments for a patient with moderate disease activity. Treatments differed in five attributes: efficacy (improvement and achieved state on disease activity), safety (probability of serious adverse events), patient's preference (level of agreement), medication costs and cost-effectiveness (incremental cost-effectiveness ratio (ICER)). A Bayesian efficient design defined 14 choice sets, and a random parameter logit model was used to estimate relative preferences for rheumatologists across countries. Cluster analyses and latent class models were applied to understand preference patterns across countries and among individual rheumatologists.Results: Responses of 559 rheumatologists from 12 European countries were included in the analysis (49% females, mean age 48 years). In all countries, efficacy dominated treatment decisions followed by economic considerations and patients’ preferences. Across countries, rheumatologists avoided selecting a treatment that patients disliked. Latent class models revealed four respondent profiles: one traded off all attributes except safety, and the remaining three classes disregarded ICER. Among individual rheumatologists, 57% disregarded ICER and these were more likely from Italy, Romania, Portugal or France, whereas 43% disregarded uncommon/rare side effects and were more likely from Belgium, Germany, Hungary, the Netherlands, Norway, Spain, Sweden or UK.Conclusions: Overall, European rheumatologists are willing to trade between treatment efficacy, patients' treatment preferences and economic considerations. However, the degree of trade-off differs between countries and among individuals.

AB - Objective: To compare the value that rheumatologists across Europe attach to patients' preferences and economic aspects when choosing treatments for patients with rheumatoid arthritis.Methods: In a discrete choice experiment, European rheumatologists chose between two hypothetical drug treatments for a patient with moderate disease activity. Treatments differed in five attributes: efficacy (improvement and achieved state on disease activity), safety (probability of serious adverse events), patient's preference (level of agreement), medication costs and cost-effectiveness (incremental cost-effectiveness ratio (ICER)). A Bayesian efficient design defined 14 choice sets, and a random parameter logit model was used to estimate relative preferences for rheumatologists across countries. Cluster analyses and latent class models were applied to understand preference patterns across countries and among individual rheumatologists.Results: Responses of 559 rheumatologists from 12 European countries were included in the analysis (49% females, mean age 48 years). In all countries, efficacy dominated treatment decisions followed by economic considerations and patients’ preferences. Across countries, rheumatologists avoided selecting a treatment that patients disliked. Latent class models revealed four respondent profiles: one traded off all attributes except safety, and the remaining three classes disregarded ICER. Among individual rheumatologists, 57% disregarded ICER and these were more likely from Italy, Romania, Portugal or France, whereas 43% disregarded uncommon/rare side effects and were more likely from Belgium, Germany, Hungary, the Netherlands, Norway, Spain, Sweden or UK.Conclusions: Overall, European rheumatologists are willing to trade between treatment efficacy, patients' treatment preferences and economic considerations. However, the degree of trade-off differs between countries and among individuals.

U2 - 10.1136/annrheumdis-2016-209202

DO - 10.1136/annrheumdis-2016-209202

M3 - Article

VL - 76

SP - 126

EP - 132

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 1

ER -